A deal for Becton Dickinson’s biosciences and diagnostic solutions unit puts Waters Corp. in a greater position to compete ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund ...

Waters Corp.'s $17.5B merger with BD Biosciences aims to double revenue but raises risks. Read here for an investment ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Life sciences firm Waters will take on $4 billion in debt, and issue 39.2% of its shares to Becton Dickinson shareholders.

According to Benzinga Pro, Becton Dickinson's peer group average for short interest as a percentage of float is 4.29%, which ...

Waters Corporation announces a $17.5 billion acquisition of Becton Dickinson's bioscience unit, expanding its reach in ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

Milford-based biotech company Waters Corp. will merge with Becton, Dickinson and Co.’s biosciences an diagnostic solutions ...